Pay-For-Performance Hits France As Part Of Cost-Cutting Measures
Executive Summary
Facing a €11 billion ($16 billion) deficit in 2009 in its state-funded health service - which is forecast to reach a whopping €17 billion next year - French ministers announced in late September a series of measures to help curb spending growth
You may also be interested in...
A Call For Action: Pharma Strategies For Development Of Payor Evidence Programs
The biopharma industry invests substantially in post-approval studies to convey information about the value of its products to constituents, but the majority of these efforts do not address core, real-world questions raised by payors. A new business model recognizing the strategic value of medical affairs to market access is needed to stem the tide of disappointing reimbursement decisions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.